Rapport Closes $410.7 Million Raise After Bipolar Trial Clears Significance At p=0.045
The biotech sold stock, notes and private shares on October 30, and now says its cash lasts through the end of 2029.
Rapport Therapeutics, a clinical-stage biotech that develops small molecule medicines for neurological and psychiatric disorders, closed financings with $410.7 million in net proceeds on October 30, according to its 10-Q filed Wednesday. The money followed an October bipolar mania readout whose main result had a p-value of 0.045, just under the usual significance cutoff.
Three pieces of a $410.7 million raise
The net proceeds break down as $215.7 million from stock, $166.8 million from 2.25% convertible senior notes due 2032 and $28.2 million from a private placement, the 10-Q says. Common stock sold at $21.00 a share, and some investors took pre-funded warrants at $20.999 instead.
The notes carry $172.5 million in principal. They convert at 37.3483 shares per $1,000, or about $26.7750 a share, roughly 27.50% above the stock offering price, and the company said in an 8-K it will settle conversions by delivering shares.
The notes are the company's first borrowing. The prior 10-Q carried no risk factor on debt, while the new one says the company incurred $172.5 million of principal and had no borrowings as of September 30.
A narrow win in bipolar mania
In the Phase 2 trial, RAP-219 beat placebo by 3.1 points on the Young Mania Rating Scale at Week 3, with p=0.045. Patients on the drug improved 15.4 points from baseline against 12.3 on placebo. Side effects were all mild or moderate, with none serious, and the company calls the result clinical proof-of-concept.
RAP-219 had already shown results in focal onset seizures, where Phase 3 is under way. Another Phase 3 trial, in primary generalized tonic-clonic seizures, is planned for the first half of 2027.
Cash runway moves to a fixed year
Cash and short-term investments stood at $395.0 million on September 30, down from $436.1 million at June 30, the company said. The company now says it can fund operations through the end of 2029. The prior filing's runway wording was into the second half of 2029.
The company lost $40.2 million in the quarter and $116.7 million over nine months. It also sold 399,201 shares under its at-the-market program for about $10 million after quarter-end. Market value was about $1.4 billion as of Wednesday morning.
Rapport plans to meet the FDA in the first quarter of 2027 on bipolar trial design, and it must file a resale registration for the private-placement shares by December 29, 2026.
Sources
- 10-Q Filing — Rapport Therapeutics (RAPP) — SEC EDGAR
- 10-Q Filing — Rapport Therapeutics (RAPP), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- 8-K Filing — Rapport Therapeutics, filed 2026-10-30 (Items 1.01, 2.02, 2.03, 3.02, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, rapp-ex99_1.htm) — Rapport Therapeutics, filed 2026-11-04 — SEC EDGAR